Hansa Biopharma AB (OTCPK:HNSBF)
$ 2.83 0 (0%) Market Cap: 240.18 Mil Enterprise Value: 254.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 72/100

Q4 2023 Hansa Biopharma AB Earnings Call Transcript

Feb 02, 2024 / 01:00PM GMT
Release Date Price: $3.3
Operator

And welcome to the Hansa Biopharma conference call covering the fourth quarter and full year 2023 earnings results. Today's call is being recorded (Operator Instructions)

SÃ;ren Tulstrup
Hansa Biopharma AB - President & CEO

¸ -

Speakers, please again Thank you, operator, and good afternoon. Good morning, and welcome to the Hansa Biopharma conference call to review year-end results for 2023. I'm Søren Tulstrup, CEO of Hansa Biopharma.

Joining me today is our Chief Commercial Officer and US President, Matt Shaulis; our Chief Financial Officer, Donato Spota; and our Chief Scientific Officer, Hitto Kaufmann, to join hands of December last year. We're thrilled to welcome here to the Hans team at this pivotal time with over 20 years' experience in research, development and advancement of science in both large pharma and small biotech organizations, eSports, solid development of our scientific platform and the advancement of our exciting pipeline of our candidates as Head of Investor Relations Klaus Sindahl, is also with us.

Today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot